Interpretation 163
Tier 1|
|
|
Tumor Types
Interpretation
NRAS mutations occur in approximately 1--6% of colorectal cancers. Several studies have shown that patients with NRAS-mutated tumors are less likely to respond to cetuximab or panitumumab, but this may not have an effect on PFS or overall survival.
Citations
- Gunderson LL et al . Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10;28(2):264-71
- JM Jessup, LL et al.. 2010 Staging System for Colon and Rectal Carcinoma. Ann. Surg. Oncol 2011 Mar 29;18(6)1513-1517
- De Roock et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010 Aug;11(8):753-62
- Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77
- Curtin et al .Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 Nov 17 ; 353 (20) :2135-47
- De Roock W, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62
- Berlin J Beyond exon 2--the developing story of RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1059-60
- De Stefano A, et al. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20(29):9732-43
Last updated: 2019-04-05 15:39:05 UTC